Titan Pharmaceuticals Inc. has completed its previously announced business combination with Black Titan Corporation, according to a company filing. The transaction, finalized on October 1, 2025, saw Titan Pharmaceuticals merge with a wholly owned subsidiary of Black Titan, making Titan a direct subsidiary of the Cayman Islands-based company. As part of the agreement, shares of Titan Pharmaceuticals were converted into ordinary shares of Black Titan. In a related move, shareholders of TalenTec Sdn. Bhd. exchanged their shares for Black Titan ordinary shares. Following the completion of the merger, Titan Pharmaceuticals' common stock is expected to cease trading on the Nasdaq Capital Market, with Black Titan's ordinary shares set to begin trading on October 2, 2025. The company also announced changes to its board, with the resignation of Titan's directors and officers and the appointment of Chay Weei Jye as sole director and acting secretary.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Titan Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-25-007823), on October 01, 2025, and is solely responsible for the information contained therein.
Comments